Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Dana-Farber Cancer Institute
Modality
Small molecule
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03936465CT.gov Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Brain Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ezobresib (this asset) | Dana-Farber Cancer Institute | P1 | CC · 47 |
| Cediranib | M.D. Anderson Cancer Center | P2 | BB |
| Temsirolimus | M.D. Anderson Cancer Center | P2 | BB |
| Sorafenib | National Cancer Institute (NCI) | P2 | BB |
| Cyclophosphamide | Essen Biotech | P3 | BB |
| Nivolumab | InSightec | P3 | BB |
| Dexmedetomidine | Kaohsiung Medical University Chung-Ho Memorial Hospital | P4 | BB |
| Irinotecan | NaviFUS Corporation | P3 | BB |
| Carboplatin | Assistance Publique - Hôpitaux de Paris | P3 | B |
+41 more in the Brain Neoplasm cohort
Other indications for Ezobresib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neoplasm | — | P1/2 | CCC · 52 |
| Childhood Neoplasm | — | P1 | CC · 47 |
| Plasma Cell Myeloma | — | P1/2 | CC · 40 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ezobresib in Brain Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ezobresib-brain-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →